{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:44:44Z","timestamp":1790415884383,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014321","name":"World Federation of Hemophilia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2024.12.038","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:17:18Z","timestamp":1736511438000},"page":"1496-1506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C.","family":"Ozelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Ribeiro","family":"Villa\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ching","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Imtiaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.12.038_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/PPA.S202773","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.12.038_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/hae.13377","article-title":"Impact of pain and functional impairment in US adults with haemophilia: patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study","volume":"24","author":"Kempton","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib4","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/hae.12545","article-title":"Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population","volume":"21","author":"Nugent","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.12.038_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.13449","article-title":"Joint disease in haemophilia: pathophysiology, pain and imaging","volume":"24","author":"van Vulpen","year":"2018","journal-title":"Haemophilia"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.12.038_bib7","first-page":"S3","article-title":"Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia","volume":"90","author":"Witkop","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.12.038_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.038_bib9","first-page":"5959","article-title":"Real-world rates of bleeding, factor VIII use, and quality of life in individuals with severe haemophilia A receiving prophylaxis in a prospective, noninterventional study","volume":"10","author":"Kenet","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib11","unstructured":"BioMarin Pharmaceutical Inc. FDA approves BioMarin\u2019s gene therapy for a genetic bleeding disorder. https:\/\/www.biomarin.com\/blog\/fda-approves-biomarins-gene-therapy-for-a-genetic-bleeding-disorder\/; 2023 [accessed July 10, 2023]."},{"key":"10.1016\/j.jtha.2024.12.038_bib12","unstructured":"BioMarin Pharmaceutical Inc. First gene therapy for adults with severe hemophilia A, BioMarin\u2019s ROCTAVIAN (valoctocogene roxaparvovec), approved by European Commission (EC). https:\/\/investors.biomarin.com\/news\/news-details\/2022\/First-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A-BioMarins-ROCTAVIAN-valoctocogene-roxaparvovec-Approved-by-European-Commission-EC-08-24-2022\/default.aspx; 2022 [accessed July 10, 2023]."},{"key":"10.1016\/j.jtha.2024.12.038_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.12.038_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib19","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib21","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.038_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.12.038_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/hae.15071","article-title":"Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.12.038_bib24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib25","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.12.038_bib27","unstructured":"Roctavian package insert. United States Food and Drug Administration. https:\/\/www.fda.gov\/media\/169937\/download; [accessed March 2024]."},{"key":"10.1016\/j.jtha.2024.12.038_bib28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.12.038_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/PROM.S357555","article-title":"Psychometric validation of the Haemo-QOL-A in participants with hemophilia A treated with gene therapy","volume":"13","author":"Quinn","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"issue":"Supplement 1","key":"10.1016\/j.jtha.2024.12.038_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140950","article-title":"Examination and validation of a patient-centric joint metric: \"Problem Joint\"; empirical evidence from the CHESS US dataset","volume":"136","author":"Burke","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.12.038_bib31","article-title":"Examination and validation of a patient-centric joint metric: \u201cPROBLEM JOINT\u201d; empirical evidence from the CHESS paediatrics dataset [abstract]; Res Pract Thromb","volume":"5","author":"Burke","year":"2021","journal-title":"Haemost"},{"key":"10.1016\/j.jtha.2024.12.038_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.omtm.2022.01.007","article-title":"Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression","volume":"24","author":"Wang","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.12.038_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/hum.2023.065","article-title":"Prophylactic prednisolone promotes AAV5 hepatocyte transduction through the novel mechanism of AAV5 coreceptor platelet-derived growth factor receptor alpha upregulation and innate immune suppression","volume":"35","author":"Handyside","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.12.038_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev-immunol-100219-020937","article-title":"Regulatory T cell development","volume":"38","author":"Savage","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jtha.2024.12.038_bib35","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.12.038_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:57:52Z","timestamp":1777618672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783625000029"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.038","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}